A phase Ia, open-label, dose-escalation study of CGX-1160 in neuropathic pain following spinal cord injury

Trial Profile

A phase Ia, open-label, dose-escalation study of CGX-1160 in neuropathic pain following spinal cord injury

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Contulakin G (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 26 Aug 2016 New trial record
    • 01 Jul 2016 Results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top